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Abstract
While morphologic and biochemical aspects of degenerative
joint disease (osteoarthritis [OA]) have been elucidated by
numerous studies, the molecular mechanisms underlying the
progressive loss of articular cartilage during OA development
remain largely unknown. The main focus of the present study
was to gain more insight into molecular changes during the very
early stages of mechanically induced cartilage degeneration and
to relate molecular alterations to histological changes at distinct
localizations of the joint. Studies on human articular cartilage are
hampered by the difficulty of obtaining normal tissue and early-
stage OA tissue, and they allow no progressive follow-up. An
experimental OA model in dogs with a slow natural history of OA
(Pond–Nuki model) was therefore chosen. Anterior cruciate
ligament transection (ACLT) was performed on 24 skeletally
mature dogs to induce joint instability resulting in OA. Samples
were taken from different joint areas after 6, 12, 24 and 48
weeks, and gene expression levels of common cartilage
molecules were quantified in relation to the histological grading
(modified Mankin score) of adjacent tissue. Histological
changes reflected early progressive degenerative OA. Soon
after ACLT, chondrocytes responded to the altered mechanical
conditions by significant and stable elevation of collagen type II,
collagen type I and YKL40 expression, which persisted
throughout the study. In contrast to the mild to moderate
histological alterations, these molecular changes were not
progressive and were independent of the joint localization (tibia,
femur, lateral, medial) and the extent of matrix degeneration.
MMP13 remained unaltered until 24 weeks, and aggrecan and
tenascinC remained unaltered until 48 weeks after ACLT. These
findings indicate that elevated collagen type II, collagen type I
and YKL40 mRNA expression levels are early and sensitive
measures of ACLT-induced joint instability independent of a
certain grade of morphological cartilage degeneration. A
second phase of molecular changes in OA may begin around 48
weeks after ACLT with altered expression of further genes, such
as MMP13, aggrecan and tenascin. Molecular changes
observed in the present study suggest that dog cartilage
responds to degenerative conditions by regulating the same
genes in a similar direction as that observed for chondrocytes in
late human OA.
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Introduction
Osteoarthritis (OA) is a disease with a high prevalence, and
it occupies a very important place in orthopedic surgery. It
is characterized by progressive degeneration of articular
cartilage and damage to subchondral bone. While macro-
scopic, histological and biochemical features of OA have
been extensively studied [1-4], the molecular changes in
chondrocyte metabolism underlying the pathophysiological
process of cartilage degeneration remain largely unknown.
Studies on human articular cartilage are hampered by the
difficulty of obtaining normal tissue and early-stage OA tis-
sue. For this reason a number of animal models have been
developed in which cartilage degeneration is induced by
causing permanent joint instability [5-7]. In the Pond–Nuki
model in dogs, anterior cruciate ligament transection
(ACLT) leads to joint laxity and altered mechanical loading
ACLT = anterior cruciate ligament transection; bp = base pair; col = collagen type; GAPDH = glyceraldehydes-3-phosphate dehydrogenase; OA = 
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in the knee joint, resulting in cartilage degeneration over
time. This model has the advantage of a fairly slow natural
history of OA, since full-thickness loss of articular cartilage
does not develop until about 4–5 years after ACLT. The
resulting degenerative changes in cartilage and synovial tis-
sue thus closely resemble those in natural canine OA and
human OA [1,4,6,8].
Recent studies have examined the gene expression levels
of collagen type (col) II, aggrecan and small proteoglycans
in dogs [9-11] and of several cartilage-related and OA-
related molecules in rabbits [12-14] over time after ACLT.
However, most of these studies used insensitive methods
of RNA detection (northern blot) [9,11], or the methods
were only semiquantitative [13,14] or failed to relate spe-
cific gene expression to the basic expression level of
housekeeping genes [9,10]. This may be one reason why
contradictory results have been obtained; for example in
rabbits, in which no alteration of col II gene expression
[12,13] or upregulation at region-specific  sites [14] is
reported. Other matrix molecules, such as aggrecan and
fibromodulin, seem to be altered only at isolated time points
[13,14]. Col II expression in dogs was reported to be
higher in ACLT-treated knees than in control knees. These
changes in col II expression progressed in one study [9]
and decreased in another one [10], while the elevation of
aggrecan was stable.
The histological appearance of OA cartilage makes it obvi-
ous that the severity of changes may vary with the location
in the joint. It has been demonstrated in the rabbit knee joint
that there are differences in RNA levels between different
cartilage regions, which emphasizes that it may be risky to
pool samples from distinct regions of the knee for molecu-
lar analysis [15]. Nonetheless, the difficulty of extracting
sufficient RNA from a limited quantity of cartilage has ham-
pered attempts to find direct correlations between the his-
tological appearance of the cartilage and the metabolism of
the chondrocytes in this region. For this reason, histological
information has either not been considered at all [9,10] or
has been derived from separate animals [12,14] in earlier
gene expression studies, although region-specific histolog-
ical progression of cartilage degeneration was reported in
the rabbit ACLT model [14].
The aim of the present study was to perform a highly sensi-
tive and quantitative molecular analysis of the response of
articular cartilage to increased joint instability and altered
mechanical loading, and thus to gain more insight into the
very early stages of mechanically induced cartilage degen-
eration. The major objective was to focus on local aspects
of gene expression with reference to the histological grad-
ing of cartilage degeneration. By improving RNA yields
from small cartilage samples and selecting highly sensitive
methods for quantitative gene expression analysis, we
studied alterations in chondrocyte metabolism side by side
with the histological appearance of cartilage degeneration
in adjacent tissue. The Pond–Nuki model was chosen
because of its close similarity to human OA, and the gene
expression levels of six OA-related molecules were fol-
lowed longitudinally over 48 weeks.
Methods
Animals
Twenty-four skeletally mature beagle dogs were each
assigned randomly to one of four experimental groups. The
animals' ages ranged from 1 to 2 years (average, 17
months) and the animal body mass was 15–22 kg (aver-
age, 19 kg). The dogs were cared for according to the
guidelines of the local Council of Animal Care. ACLT was
performed on each dog's left knee as described elsewhere
[7], with the right knee serving as the control. After 3 days
in individual indoor kennels the animals were allowed to
move about freely in groups in outdoor pens. The dogs
showed no abnormalities in posture and movement before
surgery and at euthanasia. Dogs in the four groups were
euthanized after 6, 12, 24 and 48 weeks, respectively.
Preparation of specimens
Samples were taken within 2 hours after euthanasia. A full-
thickness sample about 5 × 2 mm2 in area, including carti-
lage and bone, was excised with a hammer and chisel from
the lateral and the medial femoral condyle and from the lat-
eral and the medial tibial plateau. For molecular analysis,
articular cartilage was shaved off the articular surface 2–4
mm around the site of the histological samples and was
immersed in liquid nitrogen. Peripheral areas of cartilage
were not included.
Histology
Samples were fixed in 4% formalin, embedded in paraffin,
cut into 3-µm-thick slices and were stained with Safranin O.
Specimens were analyzed for the degree of histological
change using the Mankin score [16] modified as previously
published [17]. All sections were graded by three inde-
pendent observers blinded to the group, and median
scores were determined for statistical analysis.
Gene expression analysis
After measurement of the frozen tissue mass, cartilage
samples were pulverized in a freezer mill (Dismembrator S;
Braun Biotech, Melsungen, Germany). Messenger RNA
was extracted from the powder using oligo(dT)-coated
beads (Dynabeads; Dynal, Oslo, Norway) according to the
manufacturer's instructions, and was quantified and tested
for quality by measurement of the optical density at 280
and 260 nm in a NanoDrop ND100 photometer (Kisker,
Steinfurt, Germany). First-strand cDNA was generated
using reverse transcriptase (SuperScript II; Invitrogen Life
Technologies, Karlsruhe, Germany) and oligo(dT) primers.Available online http://arthritis-research.com/content/7/1/R156
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The cDNA was further purified using a commercially availa-
ble kit (PCR purification kit; Qiagen, Hilden, Germany). In a
pilot study, tissue requirements had been minimized to con-
fine the analysis to the close proximity around the histolog-
ical tissue sample. About 50 mg tissue was sufficient for
quantitative analysis of up to 10 genes.
Canine-specific PCR primers for GAPDH, col I, col II,
aggrecan and MMP13 were designed on the basis of gene
bank information. For tenascinC, YKL39 and YKL40
degenerated primers were applied on canine chondrocyte
cDNA to obtain specific DNA fragments. Amplified frag-
ments were purified and sequenced, and specific primers
were designed based on this sequence: GAPDH, 5'-
GATTGTCAGCAATGCCTCCT-3' and 5'-GTGGAAG-
CAGGGATGAT-GTT-3' ; col I A1, 5'-GAGAAAGAGGCT-
TCCCTGGT-3' and 5'-AGGAGAACCATCTCGTCCAG-
3' ; col II A1, 5'-TGAATGGAAGAGCGGAGACT-3' and 5'-
CCACCATTGAT-GGTTTCTCC-3' ; YKL40, 5'-TCTGTT-
GGAGGATGGAGCTT-3' and 5'-CAGCCTTCATTTC-
CTTGACC-3' ; MMP13, 5'-
CAGAGCGCTACCTGAAATCC-3' and 5'-CATTG-
TACTCGCCCACATCA-3' ; aggrecan, 5'-ACCCCT-GAG-
GAACAGGAGTT-3' and 5'-
GTGCCAGATCATCACCACAC-3'; tenascinC, 5'-
AGGGGGTCTTCGACAGTTTT-3' and 5'-CATGGCT-
GTTGTTGCTATGG-3'.
Quantitative reverse transcriptase-PCR was performed in a
LightCycler (Roche Diagnostics, Mannheim, Germany)
with optimized parameters according to the Operator's
Manual (version 3.5; Roche). Melting curves were checked
for correctness and the size of the fragments was verified
on agarose gels. In order to obtain a GAPDH standard
curve, dilutions of GAPDH cDNA in a range from 3 × 10-6
to 3 ng were subjected to LightCycler analysis. The abso-
lute amount of GAPDH mRNA contained in each cartilage
sample was obtained after LightCycler analysis by deduc-
tion from the GAPDH standard curve. A GAPDH standard
was included in every LightCycler run, and the expression
of each gene was normalized to the mRNA level of the
housekeeping gene GAPDH in the corresponding sample
(set as 100% GAPDH).
Statistics
The mean and standard deviation of each variable were
computed. The median and interquartile range were also
calculated. A two-way analysis of variance was used to
control for the side factor and for the time factor. The side
factor was analyzed as the paired measure. Post-hoc tests
were also performed to compare time points. Significant
changes were depicted. Post-hoc test results were calcu-
lated (Scheffé tests) and a two-tailed P ≤ 0.05 was consid-
ered significant. An explorative Mann–Whitney U-test and
the Wilcoxon test were chosen to evaluate differences
between two groups without alpha adjustment. Data analy-
sis was performed with SPSS for Windows 11.0.1 (SPSS
Inc., Chicago, IL, USA).
Results
The age and body mass of the animals were similar in all
experimental groups. All but one of the dogs, which was in
the 24-week group, were male. One animal had to be
excluded after euthanasia following severe injury, so that in
the 12-week group only five animals were evaluated
instead of six animals. There were no surgical complica-
tions, and none of the dogs showed clinical signs of OA,
such as altered posture or motion. The animals did not
show partially or totally restricted use of the ACLT-treated
extremity. When opened, the joints were found to show no
macroscopic signs of inflammation or cartilage degenera-
tion at 6 and 12 weeks. In those joints opened 24 weeks
after ATLC surgery incipient cartilage discoloration and
softening were seen, which were slightly more frequent and
pronounced at 48 weeks. Most dogs had an increased vol-
ume of synovial fluid in treated knees at the two later time
points.
Histological examination
Histological features observed in cartilage from ACLT-
treated knees and from control knees were similar to those
described previously [3,4,18-20]. We found slight changes
of the cartilage surface and chondrocytes at 6 weeks after
surgery but such changes appeared also in part of the con-
trol samples. Decreased Safranin O staining and loss of
zonal structure were noticeable in some specimens 12
weeks after ACLT, and were more pronounced in joints
examined 48 weeks after surgery. Chondrocyte clustering
and fissures never extending beyond the transitional zone
were observed at 24 and 48 weeks, which never extended
beyond the transitional zone. Variations in histopathological
scores were evident within each group, indicating varia-
tions in the progression of osteoarthritic changes over time
(Fig. 1). Median modified Mankin scores at 48 weeks
(12.4) were significantly higher than those at 6 weeks (7.4)
(P = 0.036), confirming progressive degeneration of carti-
lage in ACLT-treated knees. There was no obvious differ-
ence between the lateral and the medial compartments of
the tibia or of the femur (48 weeks) and no progressive
changes were obvious in the control knees over time. In
summary, the ACLT-induced changes were progressive
and consistent with early stages of OA.
Gene expression analysis
The concentration of mRNA per sample was determined
and used to calculate the absolute amount of mRNA per
milligram of tissue wet weight. The mRNA content was sim-
ilar in all study groups, providing no evidence for major dif-
ferences in RNA extraction efficiency, tissue water content
or overall transcriptional activity of cells between groups.Arthritis Research & Therapy    Vol 7 No 1    Lorenz et al.
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The absolute amount of GAPDH mRNA per total mRNA
was determined for each sample by LightCycler analysis
using a GAPDH standard curve. A considerable variability
of GAPDH per microgram of mRNA was noted that,
according to values of the control side (right knee) and the
ACLT side (left knee), primarily reflected differences
between individuals. Absolute amounts of GAPDH levels
per microgram of mRNA determined in all samples were
compared by variance analysis comprising the factors time,
side and treatment. Post-hoc tests were also performed to
analyze differences between all groups. Statistical analysis
revealed no significant differences in GAPDH levels
between any of the study groups (controls, ACLT, loca-
tions, time).
Analysis of tenascinC and the chitinase-like molecules
YKL39 and YKL40 was included in the present study
because they have been related to human OA [21-23].
Since canine DNA sequence information on tenascinC,
YKL39 and YKL40 was not available from public data-
bases, degenerated primers were designed on the basis of
multiple sequence alignment. Resulting PCR fragments for
tenascinC (923 bp) and for YKL40 (665 bp) were
sequenced, and they showed 90% and 83% nucleotide
identity with the corresponding human cDNA sequence,
respectively. The deduced protein sequence of the canine
YKL40 fragment had 83% identical and 91% similar amino
acids to human YKL40, and was only 48% identical to
human YKL39. In spite of intense primer design and PCR
analysis, it was not possible to obtain any fragments for
YKL39 from dog cartilage. The dog genome database [24]
also contained no sequence information with high homol-
ogy to human YKL39. Interestingly, in spite of eightfold
sequence coverage of the mouse genome, no YKL39
sequence is available from mouse databases and there is
no orthologous gene at the locus corresponding to the one
where human YKL39 is located. This suggested that
mouse and dog lack the YKL39 gene, while YKL40 is
present in the human, mouse, and dog.
Early upregulation of col II, YKL40 and col I
Quantitative reverse transcriptase-PCR analysis of carti-
lage from the tibial plateau revealed significant upregulation
of YKL40 and col II expression at all time points in ACLT-
treated knees compared with the untreated joints. The
median elevation was twofold to sevenfold for col II, and
was threefold to 17-fold for YKL40 (Fig. 2a,2b). Gene
expression of col I was significantly elevated at 12, 24 and
48 weeks after surgery in cartilage from the tibial plateau
(Fig. 2c). Higher expression in OA samples was also evi-
dent at 6 weeks, but owing to a large standard deviation the
difference did not reach statistical significance. There was
no significant increase or decrease over time in the levels
of col I or col II or of YKL40 in osteoarthritic cartilage. Fem-
oral condyle samples were analyzed at 48 weeks after sur-
gery. In keeping with our observations in the tibial plateau,
expression of col II and of YKL40 was significantly higher in
osteoarthritic cartilage than in control cartilage, while col I
was highly variable (Table 1).
Aggrecan, MMP13 and tenascinC expression
While mRNA levels for aggrecan tended to be lower in OA
samples than in control samples, tenascinC and MMP13
levels tended to be higher (Fig. 3). Overall, for all time
points, osteoarthritic and control knees did not differ signif-
icantly in aggrecan, MMP13 or tenascinC expression. At
24 and 48 weeks, however, MMP13 was significantly
higher in ACLT-treated knees than in normal knees (Fig.
3a). Aggrecan mRNA levels showed relatively wide varia-
tion between samples taken from animals in the same study
group, and median values tended to be slightly lower in
osteoarthritic samples than in control samples. At 48
weeks after ACLT surgery the difference was twofold, and
it reached statistical significance (P = 0.009) (Fig. 3c). In
addition, elevated levels of tenascinC were seen in OA
samples at 48 weeks after surgery (Fig. 3b). mRNA levels
of aggrecan, tenascinC and MMP13 in the femur samples
(48 weeks) were unchanged in OA samples compared
with controls (Table 1).
Region-specific differences in gene expression
Significantly higher expression of col II, YKL40 and col I
was evident in osteoarthritic samples than in normal carti-
lage samples from both the lateral and the medial tibial pla-
teau (Fig. 4a,4b,4c) at all time points studied. The results
for joints examined at all time points were pooled since no
time effects were evident for col II, col I and YKL40. On
Figure 1
Box plot of histological grading in anterior cruciate ligament transec- tion-treated knees at different times after surgery Box plot of histological grading in anterior cruciate ligament transec-
tion-treated knees at different times after surgery. Demonstrated are the 
median, standard deviation and interquartile range of the modified 
Mankin score data. White boxes, lateral tibial plateau; gray boxes, 
medial tibial plateau. * P < 0.05.Available online http://arthritis-research.com/content/7/1/R156
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average, the levels of col II in osteoarthritic joints were four-
fold those in normal joints in the lateral compartment (P <
0.001) and were sevenfold those in normal joints in the
medial compartment (P <0.001). YKL40 was elevated to
6.5-fold normal values (P < 0.001) in the lateral compart-
ment and to eightfold in the medial compartment (P  <
0.001). Expression of col I in the lateral compartment of
ACLT-treated knees was fourfold that in control joints (P =
0.004); levels in the medial compartment were 22-fold nor-
mal (P < 0.001). The baseline expression of several genes
tended to be higher in the lateral compartment than in the
medial tibial compartment, reaching significance for col II
expression (3.5-fold, P = 0.045) and for col I expression
(ninefold, P < 0.001) (Fig. 4a,4c).
A similar tendency was seen for basic YKL40 and aggre-
can expression, but not for MMP13 and tenascinC expres-
sion. In spite of region-specific baseline expression
differences, robust generalized molecular effects were
seen after ACLT surgery in canine knee cartilage, indicating
a consistent regulation of the chondrocytes' response to an
altered mechanical loading.
Figure 2
(a) Collagen type (col) II, (b) YKL-40 and (c) col I expression in carti- lage of experimental osteoarthritis (OA) at different times after surgery (a) Collagen type (col) II, (b) YKL-40 and (c) col I expression in carti-
lage of experimental osteoarthritis (OA) at different times after surgery. 
Shown are the mean relative expression levels of mRNA summarized for 
lateral and medial tibial plateau. * P < 0.05, ** P < 0.001.
Figure 3
(a) MMP13, (b) tenascinC and (c) aggrecan expression in cartilage of  experimental osteoarthritis (OA) at different times after surgery (a) MMP13, (b) tenascinC and (c) aggrecan expression in cartilage of 
experimental osteoarthritis (OA) at different times after surgery. Shown 
are the mean relative expression levels of mRNA summarized for lateral 
and medial tibial plateau. * P < 0.05, ** P < 0.001.
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No correlation between molecular changes and 
histological scoring
In order to correlate a particular histological outcome with
gene expression independently of the study group or the
location, samples adjacent to sections with extreme signs
of chondrocyte cloning and with the highest (n = 8) or the
lowest (n = 7) modified Mankin score in the ACLT-treated
group were selected. The corresponding samples were
compared with seven normal control samples (modified
Mankin score 0–2). Comparison of extreme samples prese-
lected for the highest histological scores (Fig. 5a) and the
lowest histological scores (Fig. 5b) in the ACLT group will
Figure 4
Local mRNA expression levels in cartilage of experimental osteoarthritis (OA) Local mRNA expression levels in cartilage of experimental osteoarthritis (OA): (a) collagen type (col) II, (b) col I, (c) YKL-40 and (d) aggrecan. 
Shown are mean relative expression levels of mRNA in lateral and medial tibial plateau summarized for 6, 12, 24 and 48 weeks. * P < 0.05, ** P < 
0.001.
Table 1
mRNA expression levels of osteoarthritis-relevant genes in femoral condyles at 48 weeks
Group Collagen type II YKL-40 Collagen type I Aggrecan TenascinC MMP13
Anterior cruciate 
ligament transection
1359.4* (1875.9 ± 1680.0) 1.0* (2.2 ± 2.6) 0.6 (1.4 ± 1.9) 472.0 (547.2 ± 448.6) 2.7 (11.9 ± 29.8) 0.2 (0.5 ± 0.5)
Control 121.3 (164.2 ± 150.2) 0.4 (0.3 ± 0.2) 0.7 (6.7 ± 13.2) 372.5 (434.3 ± 225.1) 1.0 (2.9 ± 2.8) 0.2 (0.7 ± 1.0)
Data presented as median (mean ± standard deviation).
* P < 0.05 versus control.Available online http://arthritis-research.com/content/7/1/R156
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increase the statistical power to detect differences that
would correlate with histological scoring. Nevertheless, we
did not obtain molecular differences between these two
ACLT groups, although both kept statistically significant
molecular differences to the contralateral control group
(Fig. 5c). Even samples with the lowest modified Mankin
score in the ACLT group had already elevated col II (P =
0.004), col I (P = 0.007) and YKL-40 (P = 0.052) expres-
sion levels. Upregulation of col II, col I and YKL-40 was thus
a very sensitive measure of cartilage degeneration that did
not progress any further during the moderate advancement
of cartilage degeneration examined in the present study.
Discussion
Although OA has been well studied, many of the basic
molecular mechanisms underlying its development are still
unknown. The use of an animal model opens up the possi-
bility of studying the early stages of disease progression
and the regional pattern of matrix degradation by compar-
ing diseased and healthy joints in the same individual. The
results presented in this report demonstrate that ACLT
leads to early and robust upregulation of the extracellular
matrix molecule col II and of YKL40 in knee cartilage, which
is independent of the time lapse since surgery, of the par-
ticular joint region studied and of the structural appearance
of the extracellular matrix in adjacent histological sections.
In addition, some evidence for a later change of gene
expression of MMP13, aggrecan and tenascinC was
obtained, which differed significantly from that on the con-
trol side by 24 and/or 48 weeks after surgery.
Our data might be interpreted as indicative of an early
phase of OA development characterized by upregulation of
col II, col I and YKL40, which is followed by a second phase
of OA progression characterized by further upregulation of
MMP13 and tenascinC. From a clinical point of view, the
possibility of differentiating successive stages of OA pro-
gression by means of early and late disease markers is
quite an attractive prospect. According to our data, col II
and YKL40 are good candidates for use as robust, early
and sensitive markers of joint instability. Although
tenascinC and MMP13 may appear on a list of potential
marker genes characterizing a second phase of OA, their
expression will deserve further attention since no difference
between ACLT samples with the lowest and the highest
modified Mankin grades is yet obvious for these molecules.
Such a distinction would be expected since cartilage
degeneration progresses with time. Since the latest time
point studied in our dog model is about 2–3 years before
full-thickness loss of articular cartilage can be anticipated,
the median and late alterations of gene expression cannot
be expected to have occurred. Longer studies will be
required to decide whether regulation of tenascinC and
MMP13 indicate a further stage of molecular alterations in
the Pond–Nuki model of OA development.
Figure 5
No correlation of molecular changes to the histological scoring No correlation of molecular changes to the histological scoring. In order to directly correlate a certain histological outcome with gene expression 
independent of the study group or the location, samples adjacent to sections with (a) the highest (n = 8) or (b) the lowest (n = 7) modified Mankin 
score (mod. MS) in the anterior cruciate ligament transection-treated group were selected and were compared with (c) seven normal control sam-
ples with the lowest mod. MS in the study. Top, representative histological sample (magnification, 40 ×); bottom, corresponding mean and standard 
deviation of the mod. MS and of gene expression levels (% GAPDH expression). col., collagen type. a P < 0.05 versus (c), b no significant difference 
versus (b), c no significant difference versus (a), d P = 0.052 versus (c), e no significant difference versus (b) and (c), f no significant difference versus 
(a) and (c).Arthritis Research & Therapy    Vol 7 No 1    Lorenz et al.
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One of the major objectives of this project was to focus on
local aspects of gene expression with reference to the his-
tological grading of cartilage degeneration. Most strikingly,
upregulation of col II, col I and YKL40 was pronounced in
ACLT-treated knees even if the histological grading of adja-
cent tissue was only weak above control level and there
was no progression with OA development (Fig. 5). Differing
levels of severity or 'doses' of injury have been suggested
by others as a possible reason for regional changes in
mRNA expression [9]. Our study, however, lends little cre-
dence to this suggestion [10,13]. Knee instability is very
likely to increase inappropriate mechanical loading in many
parts of the joint and, in keeping with this, col II and YKL40
expression rose in all locations after ACLT in our study. Sur-
prisingly, we detected significant differences in col II and
col I expression between the lateral and the medial tibial
plateau already in normal control knees, while levels of the
housekeeping gene GAPDH did not differ significantly
among the compartments at any time point of the study.
Given that mechanical forces are modulators of
chondrocyte metabolism, even physiologic loading differ-
ences may influence basal expression levels of sensitive
genes and be the explanation for this effect. This is in line
with reports of upregulation of col II and col I synthesis in
chondrocytes in response to cyclic loading in vitro [25,26].
Elevated col II and aggrecan mRNA levels were reported
previously in early-stage and median-stage canine OA after
ACLT [9,10]. In contrast to our data, however, either a pro-
gressive [9] or a declining [10] elevation of col II RNA was
observed over time in those studies. Beside the fact that
semiquantitative methods have been used in these previ-
ous studies, the normalization of gene expression data will
strongly influence the results [27]. While others decided to
express changes in mRNA expression on a per cell basis by
referring data to the DNA content of the tissue, we referred
specific mRNA expression levels to expression of the
housekeeping gene GAPDH. The strength of our method is
that we can detect a specific regulation of cartilage-rele-
vant molecules beyond generalized effects that may occur
after ACLT, such as the overall activation of chondrocyte
metabolism. Its weakness is that there is a risk that the
housekeeping gene itself may be regulated by ACLT.
Among a selection of housekeeping genes, GAPDH corre-
lated best with total RNA content per milligram of tissue in
dog cartilage [28]. Thorough statistical analysis of our data
provided no evidence for either a regulation of total mRNA
per milligram of tissue or a regulation of GAPDH in
response to ACLT at any time point of the study. Given that
the very weak trend to higher GAPDH levels after ACLT
would become significant when data are referred on a per
cell basis, the upregulation of col II, col I, YKL40, MMP13
and tenascinC per cell would be even more pronounced.
Elevated release of proteoglycan and col II protein degra-
dation products into body fluids of ACLT-treated dogs [29]
and of patients with advanced knee OA [30,31] indicate
that loss of such molecules from the cartilage matrix makes
a major contribution to the development of OA. Chondro-
cytes may sense this loss and respond to it with upregula-
tion of col II mRNA levels, but they did not adapt mRNA
levels for the aggrecan core protein accordingly in the
present study. Although there is evidence for enhanced
sulfate incorporation into proteoglycans of ACLT-treated
cartilage versus normal dog cartilage [32-34], the identity
of these molecules remained unknown. Enhanced mRNA
levels for small proteoglycans like biglycan, decorin and
fibromodulin after ACLT [11] may explain such observa-
tions, but due to the small sample size they unfortunately
could not be included in the present study.
Human chondrocytes secrete two distinct chitinase-like
molecules, called YKL39 and YKL40. While YKL40 has
been linked with tissue remodeling, with joint injury and
with  in situ inflammatory macrophages [35-40], clinical
correlates of YKL39 expression remained unknown.
Enhanced expression of YKL39, but not of YKL40, was
demonstrated in severe human OA cartilage [41,42]. How-
ever, in spite of reasonable effort, we have not been able to
detect YKL39 in canine chondrocytes and databases. The
upregulation both of YKL40 in early stages of dog OA and
of YKL39 in late-stage human OA suggests, however, that
chitinase-like molecules may have some function in carti-
lage remodeling and are potentially interesting marker mol-
ecules for osteoarthritic joint disease.
Human late-stage osteoarthritic cartilage from joint
replacement surgery subjected to cDNA array analysis
showed significantly elevated levels of col II, col I, chitinase
precursor, tenascin and several matrix metalloproteinases,
including MMP13, while aggrecan levels remain unaltered
[43]. Taking into account the high donor-dependent varia-
bility in human samples, the lower sensitivity of the cDNA
array technique than of quantitative PCR and the different
time frames studied, the overlap between molecular
alterations in natural human OA and experimental canine
OA is considerable. This indicates that chondrocytes in
dog cartilage respond to degenerative conditions by regu-
lating the same genes as chondrocytes in human OA, and
in a similar direction.
Conclusion
In conclusion, upregulation of col II, col I and YKL40 was a
very sensitive and robust response to the altered
mechanical situation after ACLT surgery, which occurred
quite independent of joint location and a certain grade of
morphological cartilage degeneration. Levels did not
progress any further during the moderate advancement of
cartilage degeneration examined in the present study, andAvailable online http://arthritis-research.com/content/7/1/R156
R164
more progressed stages of cartilage degeneration may
therefore rather be characterized by regulation of additional
cartilage-relevant molecules like MMP13 and tenascinC.
We interpret the molecular alterations in natural human OA
and experimental canine OA as considerable and we sug-
gest that the Pond–Nuki model may be a suitable experi-
mental model to unravel further basic anabolic and
catabolic molecular mechanisms of relevance for human
disease development.
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